# Gastrinoma

Suspect gastrinoma in recurrent or refractory ulcer disease, severe reflux, or secretory diarrhea with hypergastrinemia. Confirm inappropriate gastrin secretion in an acidic stomach, protect against acid-related complications immediately, then localize and stage for multidisciplinary curative or disease-control treatment.

**Clinical question:** How should physicians confirm, localize, and manage suspected gastrinoma while preventing acid-mediated complications?

Updated: 2026-09-16T00:17:15.220698+00:00

## What matters in practice
- Establish that hypergastrinemia is inappropriate by pairing fasting serum gastrin with gastric pH; gastrin >1000 pg/mL with pH <2 is considered diagnostic for gastrinoma. [20][21]
- Do not abruptly withdraw antisecretory therapy in a patient with suspected ZES; PPI interruption can expose patients to severe acid hypersecretion, while ongoing PPI therapy can cause secondary hypergastrinemia and false-positive secretin testing. [15]
- Use high-dose PPI therapy to control acid hypersecretion promptly; omeprazole 60-120 mg or an equivalent regimen is cited for ZES-associated ulceration, reflux, and diarrhea. [5]
- After biochemical confirmation or strong suspicion, localize and stage with cross-sectional imaging and endoscopic ultrasound; EUS is particularly useful for pancreatic lesions and MEN1-associated disease but detects duodenal lesions less reliably. [20][22]
- Refer localized disease for multidisciplinary surgical assessment after acid control; PPI therapy plus resection when feasible is the central curative-intent strategy. [20][21]

## Identify the phenotype that warrants biochemical testing

Test when clinical consequences suggest pathological acid hypersecretion rather than uncomplicated peptic disease.

Order fasting serum gastrin with assessment of gastric acidity in patients with recurrent or refractory peptic ulceration, severe gastroesophageal reflux, chronic diarrhea, or complications such as upper gastrointestinal bleeding, perforation, or stricturing disease. These are the actionable manifestations of gastrinoma-associated Zollinger-Ellison syndrome (ZES). [5][21]

Interpret gastrin only in physiologic context. Hypergastrinemia is the biochemical hallmark of ZES but has multiple causes; a high gastrin concentration alone does not establish gastrinoma. The diagnostic question is whether gastrin is elevated despite an acidic stomach, indicating inappropriate gastrin secretion and acid hypersecretion. [21]

Actively consider multiple endocrine neoplasia type 1 (MEN1) when gastrinoma is suspected, because gastrinomas may be sporadic or MEN1-associated and MEN1 changes tumor multiplicity, localization strategy, and operative decision-making. [11][20][22]
- Treat overt bleeding, perforation, obstruction, dehydration, or electrolyte disturbances as immediate complications before elective localization workup. Upper gastrointestinal bleeding, perforation, and strictures are recognized ZES complications. [5]
- In a patient already receiving a PPI, interpret an elevated gastrin result cautiously because acid suppression can produce secondary hypergastrinemia. [15][19]

*Clinical findings that should shift testing toward gastrinoma-associated ZES. [5][21]*

| Finding | Why it changes the next step |
| --- | --- |
| Recurrent or severe peptic ulcer disease | Obtain fasting serum gastrin and gastric pH to evaluate pathological acid hypersecretion. [5][21] |
| Severe reflux disease with chronic diarrhea | Evaluate for ZES, particularly when symptoms coexist with ulcer disease or are refractory to usual acid suppression. [5][21] |
| Upper GI bleeding, perforation, or stricture | Stabilize the complication and initiate potent acid suppression; pursue biochemical confirmation once clinically safe. [5] |
| Known or suspected MEN1 | Use EUS as part of localization and local staging because MEN1-associated disease may be multifocal. [20][22] |

## Confirm inappropriate hypergastrinemia before tumor-directed procedures

A fasting gastrin result must be paired with gastric acidity and medication context.

Measure fasting serum gastrin and gastric pH. A fasting gastrin concentration >1000 pg/mL with gastric pH <2 is considered diagnostic for gastrinoma. This combination establishes marked hypergastrinemia in the setting of persistent acid secretion, rather than hypergastrinemia secondary to hypochlorhydria or pharmacologic acid suppression. [20][21]

For patients receiving antisecretory drugs, planned medication interruption requires risk assessment and close supervision. One review describes withholding PPIs for at least 1 week and H2-receptor antagonists for 48 hours before laboratory diagnosis; however, interruption of antisecretory treatment can be hazardous in ZES, and PPI exposure can produce false-positive secretin tests. Do not use an unsupervised drug holiday solely to obtain a gastrin value in a patient with severe acid-related disease. [15][22]

Use a secretin stimulation test selectively when biochemical diagnosis remains uncertain after fasting gastrin and gastric acidity assessment. Secretin testing is not widely available, and false-positive results have been reported during PPI therapy; therefore, interpret the result with medication exposure and gastric pH rather than as a stand-alone diagnostic test. [15][20][21]

Do not pursue localization as a substitute for biochemical confirmation when the diagnosis remains equivocal. Imaging identifies tumor distribution and resectability but does not resolve the central distinction between gastrinoma and other causes of hypergastrinemia. [20][21]
- Diagnostic result: fasting gastrin >1000 pg/mL plus gastric pH <2. [20][21]
- Medication pitfall: PPIs cause secondary hypergastrinemia and may yield a false-positive secretin stimulation test. [15]
- Selected-test role: reserve secretin testing for unresolved cases after assessment of fasting gastrin, gastric acidity, and medication exposure. [20][21]

*Interpretation framework for suspected gastrinoma. [15][20][21][22]*

| Test context | Interpretation | Next action |
| --- | --- | --- |
| Fasting gastrin >1000 pg/mL and gastric pH <2 | Considered diagnostic for gastrinoma. [20][21] | Begin or optimize acid control if needed, then localize and stage disease. [20][21] |
| Elevated gastrin while taking a PPI | May represent secondary hypergastrinemia from acid suppression. [15][19] | Do not diagnose gastrinoma from gastrin alone; plan safe acidity-based evaluation. [15][21] |
| Equivocal biochemical evaluation | Secretin stimulation testing may help in selected cases but is not widely available. [20][21] | Interpret alongside PPI exposure because PPI therapy can cause false-positive testing. [15] |
| PPI withdrawal contemplated | A review describes 1 week off PPIs and 48 hours off H2 blockers for laboratory testing. [22] | Balance diagnostic yield against risk of rebound severe acid hypersecretion; avoid unsupervised interruption. [15] |

## Control acid hypersecretion before definitive tumor treatment

Acid control prevents recurrent ulcer complications and makes subsequent staging and treatment safer.

Start or intensify a proton pump inhibitor promptly in confirmed or strongly suspected ZES with ulcer disease, reflux, or diarrhea. High-dose PPI therapy, for example omeprazole 60-120 mg or an equivalent regimen, is cited for gastrinoma-associated acid hypersecretion; individual dose requirements vary, and some patients require more frequent dosing to maintain adequate acid suppression. [5][23]

Use symptom response as a clinical measure but do not equate symptom relief with mucosal healing. Regular endoscopic surveillance has been recommended because mucosal healing does not correlate reliably with symptom improvement. [23]

Reserve somatostatin analog therapy for selected patients whose hypersecretion or diarrhea remains inadequately controlled with PPI or H2-receptor blockade, or as part of management for advanced somatostatin receptor-expressing disease. Octreotide long-acting release can further reduce acid hypersecretion and improve diarrhea in some gastrinoma patients. [20][24]

Avoid acid-reducing surgery as routine management of hypersecretion; effective PPI therapy has virtually eliminated the need for acid-reducing surgical procedures. Surgical planning should focus on tumor resection, not gastrectomy for acid control, except in exceptional individualized circumstances. [23]
- Use omeprazole 60-120 mg or equivalent high-dose PPI therapy for ZES-associated acid hypersecretion. [5]
- Escalate dosing frequency when required to maintain acid suppression; a minority of patients need twice-daily or more frequent PPI administration. [23]
- Perform endoscopic surveillance rather than relying on symptom control to infer ulcer healing. [23]

*Acid-control choices in gastrinoma-associated ZES. [5][23][24]*

| Clinical problem | Action | Important limitation or monitoring point |
| --- | --- | --- |
| Ulceration, reflux, or diarrhea from acid hypersecretion | Use high-dose PPI therapy; omeprazole 60-120 mg or equivalent is cited. [5] | Symptoms may improve before mucosal healing; use endoscopic surveillance. [23] |
| Persistent need for stronger acid suppression | Increase PPI dosing frequency as needed; some patients require twice-daily or more frequent dosing. [23] | Do not stop therapy abruptly when ZES is possible because interruption can be dangerous. [15] |
| Diarrhea or hypersecretion insufficiently controlled with PPI or H2 blockade | Consider octreotide LAR in selected patients. [24] | Clinical benefit is described in some patients; coordinate use within neuroendocrine tumor management. [20][24] |

## Localize the primary and stage metastatic disease after biochemical confirmation

Localization directs resection planning and identifies liver or other metastatic disease.

Obtain imaging to localize the primary tumor and assess metastases once gastrinoma-associated ZES is biochemically established or strongly supported. Gastrinomas arise most often in the duodenum or pancreas, and the localization strategy must account for small duodenal primaries as well as pancreatic neuroendocrine tumors. [5][11][20]

Use endoscopic ultrasound (EUS) for primary localization and local staging, particularly when a pancreatic lesion or MEN1-associated disease is suspected. EUS has reported sensitivity as high as 83% for pancreatic gastrinomas but substantially lower detection rates for duodenal lesions; a negative EUS therefore does not exclude a duodenal primary. [20][22]

Add cross-sectional CT or MRI for anatomic staging and metastatic assessment. Somatostatin receptor imaging is useful for detecting primary and metastatic gastrinomas; older somatostatin receptor scintigraphy data report detection of more than 90% of patients with metastatic liver disease, although this modality should be interpreted in the context of contemporary local imaging availability and multidisciplinary planning. [12][20]

Refer patients with suspected localized, multifocal, or metastatic disease to a multidisciplinary neuroendocrine tumor team that includes gastroenterology, surgical oncology, medical oncology, radiology, nuclear medicine, and pathology. Management decisions depend on disease distribution, comorbidity, performance status, and the feasibility of complete resection. [5][20]
- EUS is most useful for pancreatic gastrinomas and MEN1-associated local staging. [20][22]
- A negative EUS does not reliably exclude a duodenal gastrinoma. [22]
- Use somatostatin receptor imaging to support detection of primary and metastatic disease. [12][20]

*Localization modalities and the decision each informs. [12][20][22]*

| Modality | Highest-value use | Key limitation |
| --- | --- | --- |
| Endoscopic ultrasound | Pancreatic primary detection and local staging; particularly useful in MEN1. [20][22] | Detection is substantially lower for duodenal lesions. [22] |
| CT or MRI | Anatomic staging and assessment for metastatic disease. [12][20] | May not identify small primary lesions. [12] |
| Somatostatin receptor imaging | Detection of primary and metastatic gastrinomas, including liver metastases. [12][20] | Use with anatomic imaging and operative planning rather than as a stand-alone resection map. [12][20] |

## Select surgery for resectable disease and disease-control therapy for advanced disease

Acid suppression is necessary in all active ZES but does not replace assessment for curative resection.

For localized gastrinoma, maintain PPI therapy and pursue surgical evaluation for curative-intent resection whenever feasible. This combined approach is described as the hallmark of localized gastrinoma treatment; surgery is directed at tumor removal after control of acid-related complications. [20][21]

The operative approach differs between sporadic and MEN1-associated ZES because MEN1 may involve multiple lesions and has a lower probability of straightforward cure. Surgical decisions should therefore integrate tumor localization, extent of disease, MEN1 status, and the ability to achieve negative microscopic margins. [12][23]

After resection, follow serum gastrin; an elevated postoperative gastrin should trigger imaging for recurrent or persistent disease. Management of recurrent or metastatic disease remains individualized, but aggressive resection or cytoreduction is favored in the cited surgical review. [23]

For unresectable or metastatic disease, continue acid suppression and consider somatostatin analogs, peptide receptor radionuclide therapy (PRRT), liver-directed embolization approaches, systemic chemotherapy, or tyrosine kinase inhibitors according to disease burden, receptor expression, symptoms, and multidisciplinary review. These options are listed for advanced gastrinoma management, not as interchangeable first-line therapies. [5][20]
- Localized, resectable disease: PPI therapy plus surgical resection with curative intent. [20][21]
- Postoperative surveillance: measure gastrin; if it rises, obtain imaging for recurrence or persistent disease. [23]
- Advanced disease: choose somatostatin analogs, PRRT, liver-directed therapy, chemotherapy, or tyrosine kinase inhibitors according to disease pattern and multidisciplinary assessment. [5][20]

*Treatment branch after localization and staging. [5][20][21][23]*

| Disease state | Core management | Monitoring or escalation |
| --- | --- | --- |
| Localized and resectable gastrinoma | Continue PPI therapy and refer for curative-intent resection. [20][21] | Measure postoperative gastrin; image if gastrin becomes elevated. [23] |
| MEN1-associated or multifocal disease | Individualize surgery according to multiplicity, localization, and likelihood of complete resection. [12][23] | Use EUS for local staging and multidisciplinary surgical planning. [20][22] |
| Unresectable or metastatic disease | Maintain acid control; consider somatostatin analogs, PRRT, liver-directed embolization, chemotherapy, or tyrosine kinase inhibitors. [5][20] | Select modality by metastatic burden and pattern, comorbidity, age, and performance status. [20] |

## References
1. Pathology of Gastrointestinal Neuroendocrine Tumors — thelancet.com — http://thelancet.com/article/S1875-9181(10)00017-6/pdf
2. Pancreatic Endocrine Tumors With Major Vascular Abutment ... — jamanetwork.com — https://jamanetwork.com/journals/archsurg/articlepdf/10.1001/archsurg.2011.129
3. Lymph Nodes and Survival in Pancreatic Neuroendocrine Tumors — jamanetwork.com — https://jamanetwork.com/journals/jamasurgery/fullarticle/1358522
4. The British Society of Gastroenterology - Gut — gut.bmj.com — https://gut.bmj.com/content/gutjnl/23/10/A880.full.pdf
5. British Society of Gastroenterology practice guidance on the management of acute and chronic gastrointestinal symptoms and complications as a result of treatment for cancer — gut.bmj.com — https://gut.bmj.com/content/early/2025/03/26/gutjnl-2024-333812.full.pdf
6. H 2 -Histamine Receptor Blocking Agents in the Zollinger-Ellison ... — annals.org — https://annals.org/doi/10.7326/0003-4819-87-6-668
7. Peptic Ulcer: New Therapies, New Diseases - Ovid — annals.org — https://annals.org/data/journals/aim/19578/aime198111010-00016.pdf
8. Comparison of Ranitidine and Cimetidine in the Treatment ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-100-1-52
9. Zollinger-Ellison Syndrome: Current Concepts and ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-98-1-59
10. Somatostatin Receptor Scintigraphy: Its Sensitivity ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-125-1-199607010-00005
11. All you need to know about gastrinoma today | Gastrinoma and Zollinger‐Ellison syndrome: A thorough update - Chatzipanagiotou - 2023 - Journal of Neuroendocrinology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/abs/10.1111/jne.13267
12. Zollinger Ellison Syndrome - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/nursing-and-health-professions/zollinger-ellison-syndrome
13. Total gastrectomy for severe proton pump inhibitor-induced hypomagnesemia in a MEN1/Zollinger Ellison syndrome patient - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1424390320308620
14. Surgery for Gastrinoma: Short and Long-Term Results - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2173507715001477
15. False-Positive Secretin Stimulation Test for Gastrinoma Associated With the Use of Proton Pump Inhibitor Therapy - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1542356509001426
16. Pancreatic Endocrine Tumors: Radiologic-Clinicopathologic ... — pubs.rsna.org — https://pubs.rsna.org/doi/10.1148/rg.306105523
17. Metastatic gastrinomas: localization with selective arterial injection ... — pubs.rsna.org — https://pubs.rsna.org/doi/10.1148/radiology.198.1.8539410
18. localization with selective arterial injection of secretin.Radiology — pubs.rsna.org — https://pubs.rsna.org/doi/full/10.1148/radiology.198.1.8539410
19. Protocol Phase 2-4 Template — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/59/NCT03050359/Prot_000.pdf
20. Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475006
21. Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34629807
22. All you need to know about gastrinoma today | Gastrinoma and Zollinger-Ellison syndrome: A thorough update - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/37042078
23. Zollinger-Ellison Syndrome: Classical Considerations and Current Controversies - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903066
24. [PDF] sandostatin-lar-article-30-referral-annex-iii_en.pdf — www.ema.europa.eu — https://www.ema.europa.eu/en/documents/referral/sandostatin-lar-article-30-referral-annex-iii_en.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.